(S)-tetrahydrofuran-3-yl acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢呋喃
• 英文名称: (S)-tetrahydrofuran-3-yl acetate
• 英文别名: (S)-3-tetrahydrofuryl acetate；(S)-tetrahydrofuryl-3-acetate；[(3S)-oxolan-3-yl] acetate
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: DIRLDPKYOATBIA-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-tetrahydrofuran-3-yl acetate 在 sodium hydroxide 作用下， 以 甲醇 、 水 为溶剂， 反应 3.0h， 以83%的产率得到(S)-3-羟基四氢呋喃
  参考文献：
  名称：

  一种药物中间体(S)-3-羟基四氢呋喃的制备方法

  摘要：

  本发明提供了一种药物中间体(S)‑3‑羟基四氢呋喃的制备方法。本方法以外消旋的1,2,4‑丁三醇为原料合成外消旋的3‑羟基四氢呋喃，然后酯化得到外消旋的四氢呋喃基‑3‑脂肪酸酯。通过脂肪酶水解该外消旋混合物中的(R)‑四氢呋喃基‑3‑脂肪酸酯后，在不对水解产物进行分离的条件下，利用光延反应将水解得到的(R)‑3‑羟基四氢呋喃转化为(S)‑四氢呋喃基‑3‑羧酸酯，最后在碱性条件下将所有的四氢呋喃基酯水解得到终产物(S)‑3‑羟基四氢呋喃。

  公开号：

  CN106957287A
• 作为产物：
  描述：

  (+/-)-tetrahydrofuran-3-yl acetate 在 crude extract of Escherichia coli DH5α cells containing Bacillus stearothermophilus esterase, V224Y mutant 作用下， 以 aq. phosphate buffer 为溶剂， 反应 42.0h， 生成 (R)-(-)-3-羟基四氢呋喃 、 (S)-tetrahydrofuran-3-yl acetate
  参考文献：
  名称：

  Use of ‘small but smart’ libraries to enhance the enantioselectivity of an esterase fromBacillus stearothermophilustowards tetrahydrofuran-3-yl acetate

  摘要：

  Two libraries of simultaneous double mutations in the active site region of an esterase from Bacillus stearothermophilus were constructed to improve the enantioselectivity in the hydrolysis of tetrahydrofuran‐3‐yl acetate. As screening of large mutant libraries is hampered by the necessity for GC/MS analysis, mutant libraries were designed according to a ‘small but smart’ concept. The design of focused libraries was based on data derived from a structural alignment of 3317 amino acid sequences of α/β‐hydrolase fold enzymes with the bioinformatic tool 3dm. In this way, the number of mutants to be screened was substantially reduced as compared with a standard site‐saturation mutagenesis approach. Whereas the wild‐type esterase showed only poor enantioselectivity (E = 4.3) in the hydrolysis of (S)‐tetrahydrofuran‐3‐yl acetate, the best variants obtained with this approach showed increased E‐values of up to 10.4. Furthermore, some variants with inverted enantiopreference were found.

  DOI：

  10.1111/febs.12137

文献信息

• HYDRAZIDE-CONTAINING HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：MOORE JOEL D.

  公开号：US20080269228A1

  公开（公告）日：2008-10-30

  The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I或式II的新型含酰肼化合物，包括抑制丝氨酸蛋白酶活性的药物可接受的盐、酯或前药，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还作为抗病毒剂是有用的。本发明进一步涉及包含上述化合物的药物组合物，用于给患有HCV感染的对象进行给药。本发明还涉及通过管理包含本发明化合物的药物组合物来治疗对象中的HCV感染的方法。
• [EN] HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS<br/>[FR] MODULATEURS HÉTÉROCYCLIQUES DE LA SYNTHÈSE DES LIPIDES
  申请人：3 V BIOSCIENCES INC

  公开号：WO2012122391A1

  公开（公告）日：2012-09-13

  Compounds that are fatty acid synthesis modulators are provided. The compounds may be used to treat disorders characterized by disregulation of the fatty acid synthase function by modulating the function and/or the fatty acid synthase pathway. Methods are provided for treating such disorders including viral infections, such as hepatits C infection, cancer and metabolic disorders.

  提供了一些脂肪酸合成调节剂。这些化合物可用于治疗由于调节脂肪酸合酶功能不当而表现出的紊乱的疾病，通过调节功能和/或脂肪酸合酶途径。提供了用于治疗此类疾病的方法，包括病毒感染，如丙型肝炎感染，癌症和代谢性疾病。
• [EN] HETEROARYL COMPOUNDS FOR KINASE INHIBITION<br/>[FR] COMPOSÉS HÉTÉROARYLE D'INHIBITION DE LA KINASE
  申请人：ARIAD PHARMA INC

  公开号：WO2015195228A1

  公开（公告）日：2015-12-23

  Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括突变的EGFR和突变的HER2激酶活性，以及与激酶活性相关的疾病和病况的治疗方法、化合物、药物组合物，包括突变的EGFR和突变的HER2活性，均在本文中描述。
• [EN] BROADSPECTRUM SUBSTITUTED BENZIMIDAZOLE SULFONAMIDE HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTEASE DE VIH A BASE DE BENZIMIDAZOLE SULFONAMIDE SUBSTITUES A LARGE SPECTRE
  申请人：TIBOTEC PHARM LTD

  公开号：WO2003076413A1

  公开（公告）日：2003-09-18

  The present invention concerns the compounds having the formula (I), wherein N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aRl0b)CR9-; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is -C(=O)-, -O-C(=O)-, -NR8-C(=O)-, -O-C1-6alkanediyl-C(=O)-, -NR8-C1-6alkanediyl-C(=O)-, -S(=O)2-, -O-S(=O)2-, -NR8-S(=O)2 ; R3 is C1-6alkyl, aryl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, or arylC1-4alkyl; R4 is H, C1-4alkylOC(=O), carboxyl, aminoC(=O), mono- or di(C1-4alkyl)aminoC(=O), C3-7cycloalkyl, C2-6alkenyl, C2-6alkynyl or optionally substituted C1-6alkyl; A is C1-6alkanediyl, -C(=O)-, -C(=S)-, -S(=O)2-, C1-6alkanediyl-C(=O)-, C1-6 alkanediyl-C(=S)- or C1-6alkanediyl-S(=O)2-; R5 is H, OH, C1-6alkyl, Het1C1-6alkyl, Het2C1-6 alkyl, optionally substituted amino­-C1-6alkyl; R6 is C1-6alkylO, Het1, Het1O, Het2, Het2O, aryl, arylO, C1-6 alkyloxy­carbonylamino or amino; and in case _A- is other than C1-6alkanediyl then R6 may also be C1-6alkyl, Het1C1-4alkyl, Het1OC1-4alkyl, Het2C1-4alkyl, Het2OC1-4alkyl, arylC1-4alkyl, arylOC1-4alkyl or aminoC1-4alkyl; whereby each of the amino groups in the definition of R6 may optionally be substituted; R5 and _A-R6 taken together with the nitrogen atom to which they are attached may also form Het1 or Het2, R12 , is H, - NH2, _NR5AR6, - C1-6alkyl or alkyl-W-R14 , wherein said alkyl is optionally substituted with halogen, hydroxy, aryl, heteroaryl, Het1, Het2, or amino wherein said amino is optionally mono- or di-substituted with C1-4alkyl and R13 is H, C1-6-alkyl, optionally substituted by aryl, Het1, Het2, hydroxy, halogen, amino whereby the amino group may be optionally be mono- or di-substituted with C1-4alkyl.

  本发明涉及具有以下式（I）的化合物，其中N-氧化物，盐，立体异构体形式，消旋混合物，前药，酯及其代谢物，其中R1和R8各自为H，可选择地取代的C1-6烷基，C2-6烯基，C3-7环烷基，芳基，Het1，Het2；R1也可以是具有式（R11aR11b）NC（R10aRl0b）CR9-的基团；t为0、1或2；R2为H或C1-6烷基；L为-C（=O）-，-O-C（=O）-，-NR8-C（=O）-，-O-C1-6烷二基-C（=O）-，-NR8-C1-6烷二基-C（=O）-，-S（=O）2-，-O-S（=O）2-，-NR8-S（=O）2；R3为C1-6烷基，芳基，C3-7环烷基，C3-7环烷基C1-4烷基，或芳基C1-4烷基；R4为H，C1-4烷基OC（=O），羧基，氨基C（=O），单或双（C1-4烷基）氨基C（=O），C3-7环烷基，C2-6烯基，C2-6炔基或可选择地取代的C1-6烷基；A为C1-6烷二基，-C（=O）-，-C（=S）-，-S（=O）2-，C1-6烷二基-C（=O）-，C1-6烷二基-C（=S）-或C1-6烷二基-S（=O）2-；R5为H，OH，C1-6烷基，Het1C1-6烷基，Het2C1-6烷基，可选择地取代的氨基-C1-6烷基；R6为C1-6烷氧，Het1，Het1O，Het2，Het2O，芳基，芳基O，C1-6烷氧基羰基氨基或氨基；如果A-不是C1-6烷二基，则R6也可以是C1-6烷基，Het1C1-4烷基，Het1OC1-4烷基，Het2C1-4烷基，Het2OC1-4烷基，芳基C1-4烷基，芳基OC1-4烷基或氨基C1-4烷基；在R6的定义中，每个氨基也可以选择性地被取代；R5和A-R6连同它们连接的氮原子一起也可以形成Het1或Het2，R12为H，-NH2，A-NR5AR6，-C1-6烷基或烷基-W-R14，其中所述烷基可选择性地用卤素，羟基，芳基，杂环芳基，Het1，Het2或氨基取代，其中所述氨基可选择性地单取代或双取代为C1-4烷基，R13为H，C1-6-烷基，可选择地被芳基，Het1，Het2，羟基，卤素，氨基取代，其中所述氨基可选择性地单取代或双取代为C1-4烷基。
• [EN] SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICES A BASE D'HYDROXAMATES CYCLIQUES SUBSTITUES
  申请人：INCYTE CORP

  公开号：WO2005037826A1

  公开（公告）日：2005-04-28

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式I的化合物：其对映异构体，二对映异构体，混合物，前药，结晶形式，非晶形式，无定形形式，溶剂化物，代谢物和药学上可接受的盐，其中环A取代基在以下披露中被完全定义。公式I的化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要MMPs抑制的疾病中有用。